Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

DLC3 suppresses MT1-MMP-dependent matrix degradation by controlling RhoB and actin remodeling at endosomal membranes.

Noll B, Benz D, Frey Y, Meyer F, Lauinger M, Eisler SA, Schmid S, Hordijk PL, Olayioye MA.

J Cell Sci. 2019 Jun 5;132(11). pii: jcs223172. doi: 10.1242/jcs.223172.

PMID:
31076513
2.

The tumor suppressor protein DLC1 maintains protein kinase D activity and Golgi secretory function.

Jensch A, Frey Y, Bitschar K, Weber P, Schmid S, Hausser A, Olayioye MA, Radde NE.

J Biol Chem. 2018 Sep 14;293(37):14407-14416. doi: 10.1074/jbc.RA118.003787. Epub 2018 Jul 25.

PMID:
30045871
3.

A Rho signaling network links microtubules to PKD controlled carrier transport to focal adhesions.

Eisler SA, Curado F, Link G, Schulz S, Noack M, Steinke M, Olayioye MA, Hausser A.

Elife. 2018 Jul 20;7. pii: e35907. doi: 10.7554/eLife.35907.

4.

m6A RNA Degradation Products Are Catabolized by an Evolutionarily Conserved N6-Methyl-AMP Deaminase in Plant and Mammalian Cells.

Chen M, Urs MJ, Sánchez-González I, Olayioye MA, Herde M, Witte CP.

Plant Cell. 2018 Jul;30(7):1511-1522. doi: 10.1105/tpc.18.00236. Epub 2018 Jun 8.

5.

Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.

Schmitt LC, Rau A, Seifert O, Honer J, Hutt M, Schmid S, Zantow J, Hust M, Dübel S, Olayioye MA, Kontermann RE.

MAbs. 2017 Jul;9(5):831-843. doi: 10.1080/19420862.2017.1319023. Epub 2017 Apr 19.

6.

miR-181 elevates Akt signaling by co-targeting PHLPP2 and INPP4B phosphatases in luminal breast cancer.

Strotbek M, Schmid S, Sánchez-González I, Boerries M, Busch H, Olayioye MA.

Int J Cancer. 2017 May 15;140(10):2310-2320. doi: 10.1002/ijc.30661. Epub 2017 Mar 11.

7.

Applying phasor approach analysis of multiphoton FLIM measurements to probe the metabolic activity of three-dimensional in vitro cell culture models.

Lakner PH, Monaghan MG, Möller Y, Olayioye MA, Schenke-Layland K.

Sci Rep. 2017 Feb 13;7:42730. doi: 10.1038/srep42730.

8.

ATF6β-based fine-tuning of the unfolded protein response enhances therapeutic antibody productivity of Chinese hamster ovary cells.

Pieper LA, Strotbek M, Wenger T, Olayioye MA, Hausser A.

Biotechnol Bioeng. 2017 Jun;114(6):1310-1318. doi: 10.1002/bit.26263.

PMID:
28165157
9.

Secretory pathway optimization of CHO producer cells by co-engineering of the mitosRNA-1978 target genes CerS2 and Tbc1D20.

Pieper LA, Strotbek M, Wenger T, Gamer M, Olayioye MA, Hausser A.

Metab Eng. 2017 Mar;40:69-79. doi: 10.1016/j.ymben.2017.01.003. Epub 2017 Jan 11.

10.

Spatial Rho regulation: Molecular mechanisms controlling the GAP protein DLC3.

Hendrick J, Olayioye MA.

Small GTPases. 2019 Jan;10(1):13-19. doi: 10.1080/21541248.2016.1260673. Epub 2016 Dec 21.

11.

The polarity protein Scribble positions DLC3 at adherens junctions to regulate Rho signaling.

Hendrick J, Franz-Wachtel M, Moeller Y, Schmid S, Macek B, Olayioye MA.

J Cell Sci. 2016 Oct 1;129(19):3583-3596. Epub 2016 Aug 5.

12.

Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling.

Möller Y, Morkel M, Schmid J, Beyes S, Hendrick J, Strotbek M, Riemer P, Schmid S, Schmitt LC, Kontermann R, Mürdter T, Schwab M, Sers C, Olayioye MA.

Oncotarget. 2016 Aug 16;7(33):53526-53539. doi: 10.18632/oncotarget.10658.

13.

Rho regulation: DLC proteins in space and time.

Braun AC, Olayioye MA.

Cell Signal. 2015 Aug;27(8):1643-51. doi: 10.1016/j.cellsig.2015.04.003. Epub 2015 Apr 16. Review.

PMID:
25889896
14.

A computational model of PKD and CERT interactions at the trans-Golgi network of mammalian cells.

Weber P, Hornjik M, Olayioye MA, Hausser A, Radde NE.

BMC Syst Biol. 2015 Feb 26;9:9. doi: 10.1186/s12918-015-0147-1.

15.

The Rho-specific GAP protein DLC3 coordinates endocytic membrane trafficking.

Braun AC, Hendrick J, Eisler SA, Schmid S, Hausser A, Olayioye MA.

J Cell Sci. 2015 Apr 1;128(7):1386-99. doi: 10.1242/jcs.163857. Epub 2015 Feb 11.

16.

A global microRNA screen identifies regulators of the ErbB receptor signaling network.

Bischoff A, Bayerlová M, Strotbek M, Schmid S, Beissbarth T, Olayioye MA.

Cell Commun Signal. 2015 Jan 29;13:5. doi: 10.1186/s12964-015-0084-z.

17.

B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.

Herr R, Köhler M, Andrlová H, Weinberg F, Möller Y, Halbach S, Lutz L, Mastroianni J, Klose M, Bittermann N, Kowar S, Zeiser R, Olayioye MA, Lassmann S, Busch H, Boerries M, Brummer T.

Cancer Res. 2015 Jan 1;75(1):216-29. doi: 10.1158/0008-5472.CAN-13-3686. Epub 2014 Nov 7.

18.

EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells.

Möller Y, Siegemund M, Beyes S, Herr R, Lecis D, Delia D, Kontermann R, Brummer T, Pfizenmaier K, Olayioye MA.

PLoS One. 2014 Sep 8;9(9):e107165. doi: 10.1371/journal.pone.0107165. eCollection 2014.

19.

miR149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion.

Bischoff A, Huck B, Keller B, Strotbek M, Schmid S, Boerries M, Busch H, Müller D, Olayioye MA.

Cancer Res. 2014 Sep 15;74(18):5256-65. doi: 10.1158/0008-5472.CAN-13-3319. Epub 2014 Jul 17.

20.

A WXW motif is required for the anticancer activity of the TAT-RasGAP317-326 peptide.

Barras D, Chevalier N, Zoete V, Dempsey R, Lapouge K, Olayioye MA, Michielin O, Widmann C.

J Biol Chem. 2014 Aug 22;289(34):23701-11. doi: 10.1074/jbc.M114.576272. Epub 2014 Jul 9.

21.

Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger.

Jaiswal M, Dvorsky R, Amin E, Risse SL, Fansa EK, Zhang SC, Taha MS, Gauhar AR, Nakhaei-Rad S, Kordes C, Koessmeier KT, Cirstea IC, Olayioye MA, Häussinger D, Ahmadian MR.

J Biol Chem. 2014 Mar 7;289(10):6839-49. doi: 10.1074/jbc.M113.527655. Epub 2014 Jan 17.

22.

Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation.

Huck B, Duss S, Hausser A, Olayioye MA.

J Biol Chem. 2014 Feb 7;289(6):3138-47. doi: 10.1074/jbc.M113.502633. Epub 2013 Dec 11.

23.

Stable microRNA expression enhances therapeutic antibody productivity of Chinese hamster ovary cells.

Strotbek M, Florin L, Koenitzer J, Tolstrup A, Kaufmann H, Hausser A, Olayioye MA.

Metab Eng. 2013 Nov;20:157-66. doi: 10.1016/j.ymben.2013.10.005. Epub 2013 Oct 18.

24.

Multi-level control of actin dynamics by protein kinase D.

Olayioye MA, Barisic S, Hausser A.

Cell Signal. 2013 Sep;25(9):1739-47. doi: 10.1016/j.cellsig.2013.04.010. Epub 2013 May 18. Review.

PMID:
23688773
25.

PKD controls mitotic Golgi complex fragmentation through a Raf-MEK1 pathway.

Kienzle C, Eisler SA, Villeneuve J, Brummer T, Olayioye MA, Hausser A.

Mol Biol Cell. 2013 Feb;24(3):222-33. doi: 10.1091/mbc.E12-03-0198. Epub 2012 Dec 14.

26.

GIT1 phosphorylation on serine 46 by PKD3 regulates paxillin trafficking and cellular protrusive activity.

Huck B, Kemkemer R, Franz-Wachtel M, Macek B, Hausser A, Olayioye MA.

J Biol Chem. 2012 Oct 5;287(41):34604-13. doi: 10.1074/jbc.M112.374652. Epub 2012 Aug 13.

27.

Loss of the ceramide transfer protein augments EGF receptor signaling in breast cancer.

Heering J, Weis N, Holeiter M, Neugart F, Staebler A, Fehm TN, Bischoff A, Schiller J, Duss S, Schmid S, Korte T, Herrmann A, Olayioye MA.

Cancer Res. 2012 Jun 1;72(11):2855-66. doi: 10.1158/0008-5472.CAN-11-3069. Epub 2012 Apr 3.

28.

Integration of non-vesicular and vesicular transport processes at the Golgi complex by the PKD-CERT network.

Olayioye MA, Hausser A.

Biochim Biophys Acta. 2012 Aug;1821(8):1096-103. doi: 10.1016/j.bbalip.2011.12.005. Epub 2011 Dec 30. Review.

PMID:
22226883
29.

The RhoGAP protein Deleted in Liver Cancer 3 (DLC3) is essential for adherens junctions integrity.

Holeiter G, Bischoff A, Braun AC, Huck B, Erlmann P, Schmid S, Herr R, Brummer T, Olayioye MA.

Oncogenesis. 2012 Jun 4;1:e13. doi: 10.1038/oncsis.2012.13.

30.

The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation.

Scholz RP, Gustafsson JO, Hoffmann P, Jaiswal M, Ahmadian MR, Eisler SA, Erlmann P, Schmid S, Hausser A, Olayioye MA.

Exp Cell Res. 2011 Feb 15;317(4):496-503. doi: 10.1016/j.yexcr.2010.11.003. Epub 2010 Nov 16.

PMID:
21087603
31.

DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain.

Erlmann P, Schmid S, Horenkamp FA, Geyer M, Pomorski TG, Olayioye MA.

Mol Biol Cell. 2009 Oct;20(20):4400-11. doi: 10.1091/mbc.E09-03-0247. Epub 2009 Aug 26.

32.

Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status.

Murphy NC, Biankin AV, Millar EK, McNeil CM, O'Toole SA, Segara D, Crea P, Olayioye MA, Lee CS, Fox SB, Morey AL, Christie M, Musgrove EA, Daly RJ, Lindeman GJ, Henshall SM, Visvader JE, Sutherland RL.

Int J Cancer. 2010 Mar 15;126(6):1445-53. doi: 10.1002/ijc.24826.

33.

Protein kinase D regulates cell migration by direct phosphorylation of the cofilin phosphatase slingshot 1 like.

Peterburs P, Heering J, Link G, Pfizenmaier K, Olayioye MA, Hausser A.

Cancer Res. 2009 Jul 15;69(14):5634-8. doi: 10.1158/0008-5472.CAN-09-0718. Epub 2009 Jun 30.

34.

Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration.

Heering J, Erlmann P, Olayioye MA.

Exp Cell Res. 2009 Sep 10;315(15):2505-14. doi: 10.1016/j.yexcr.2009.05.022. Epub 2009 May 29.

PMID:
19482022
35.

Heterologous expression of the lipid transfer protein CERT increases therapeutic protein productivity of mammalian cells.

Florin L, Pegel A, Becker E, Hausser A, Olayioye MA, Kaufmann H.

J Biotechnol. 2009 Apr 20;141(1-2):84-90. doi: 10.1016/j.jbiotec.2009.02.014. Epub 2009 Mar 6.

PMID:
19428735
36.

DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling.

Scholz RP, Regner J, Theil A, Erlmann P, Holeiter G, Jähne R, Schmid S, Hausser A, Olayioye MA.

J Cell Sci. 2009 Jan 1;122(Pt 1):92-102. doi: 10.1242/jcs.036251. Epub 2008 Dec 9.

37.

Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway.

Holeiter G, Heering J, Erlmann P, Schmid S, Jähne R, Olayioye MA.

Cancer Res. 2008 Nov 1;68(21):8743-51. doi: 10.1158/0008-5472.CAN-08-0984.

38.

Regulation of secretory transport by protein kinase D-mediated phosphorylation of the ceramide transfer protein.

Fugmann T, Hausser A, Schöffler P, Schmid S, Pfizenmaier K, Olayioye MA.

J Cell Biol. 2007 Jul 2;178(1):15-22. Epub 2007 Jun 25.

39.

Phosphorylation of StarD10 on serine 284 by casein kinase II modulates its lipid transfer activity.

Olayioye MA, Buchholz M, Schmid S, Schöffler P, Hoffmann P, Pomorski T.

J Biol Chem. 2007 Aug 3;282(31):22492-8. Epub 2007 Jun 8.

40.

CPAP interacts with 14-3-3 in a cell cycle-dependent manner.

Chen CY, Olayioye MA, Lindeman GJ, Tang TK.

Biochem Biophys Res Commun. 2006 Apr 21;342(4):1203-10. Epub 2006 Feb 24.

PMID:
16516142
41.

StarD10, a START domain protein overexpressed in breast cancer, functions as a phospholipid transfer protein.

Olayioye MA, Vehring S, Müller P, Herrmann A, Schiller J, Thiele C, Lindeman GJ, Visvader JE, Pomorski T.

J Biol Chem. 2005 Jul 22;280(29):27436-42. Epub 2005 May 23.

42.
43.

XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland.

Olayioye MA, Kaufmann H, Pakusch M, Vaux DL, Lindeman GJ, Visvader JE.

Cell Death Differ. 2005 Jan;12(1):87-90. No abstract available.

44.

The phosphoprotein StarD10 is overexpressed in breast cancer and cooperates with ErbB receptors in cellular transformation.

Olayioye MA, Hoffmann P, Pomorski T, Armes J, Simpson RJ, Kemp BE, Lindeman GJ, Visvader JE.

Cancer Res. 2004 May 15;64(10):3538-44.

45.

Threonine 391 phosphorylation of the human prolactin receptor mediates a novel interaction with 14-3-3 proteins.

Olayioye MA, Guthridge MA, Stomski FC, Lopez AF, Visvader JE, Lindeman GJ.

J Biol Chem. 2003 Aug 29;278(35):32929-35. Epub 2003 Jun 20.

46.

Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4.

Orend G, Huang W, Olayioye MA, Hynes NE, Chiquet-Ehrismann R.

Oncogene. 2003 Jun 19;22(25):3917-26.

PMID:
12813465
47.
48.

The ErbB receptor tyrosine family as signal integrators.

Hynes NE, Horsch K, Olayioye MA, Badache A.

Endocr Relat Cancer. 2001 Sep;8(3):151-9. Review.

PMID:
11566606
49.

An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway.

Olayioye MA, Badache A, Daly JM, Hynes NE.

Exp Cell Res. 2001 Jul 1;267(1):81-7.

PMID:
11412040
50.

Characterization of an N-terminally truncated cyclin A isoform in mammalian cells.

Kaufmann H, Marone R, Olayioye MA, Bailey JE, Fussenegger M.

J Biol Chem. 2001 Aug 10;276(32):29987-93. Epub 2001 Jun 11.

Supplemental Content

Loading ...
Support Center